Navigation Links
ESC calls for research into vulnerable plaques
Date:6/14/2011

Sophia Antipolis, France: Tuesday 14 June : The European Society of Cardiology (ESC) Working Group of Atherosclerosis and Vascular Biology has published a position paper to raise the profile of vulnerable plaques and the need for greater use of therapies to promote plaque stabilisation. The position paper, published online today in Thrombosis and Haemostasis, is also calling for more research into the causes of plaque rupture, and for the development of better diagnostics and treatments.

"We want more medical professionals to understand the concept that stabilising vulnerable plaques offers a fundamental approach to preventing cardiovascular events," said Seppo Yl-Herttuala, chairman of the position paper task force. Indeed, he added, several statin trials for secondary prevention have reported a reduction in cardiovascular events, and furthermore anti platelet therapies have been shown to have a beneficial effect.

"Introducing stabilisation of vulnerable plaques as part of secondary prevention would offer the opportunity to wipe out half of coronary events," said Yl-Herttuala, from University of Eastern Finland (Kuopio, Finland).

"Wide spread stabilization of vulnerable plaques would also have important socio economic implications dramatically reducing the need for invasive treatments," said Christian Weber, also a member of the working group.

The idea of vulnerable plaques is that not all plaques (the fatty deposits in arterial walls) are equal and that some are particularly prone to rupture and causing cardiovascular events . These plaques are not necessarily the same as those that cause symptoms such as angina. Explaining the concept of vulnerable plaques, Weber, from Ludwig-Maximilians-University (Munich, Germany) said that it is thought that inflammatory cells resulting from ongoing inflammation destabilise the structure of the plaque. "It is believed that they degrade the fibres that make the plaque stable, leading to a greater potential for the plaque to rupture," he said.

The concept of plaque stabilisation was introduced to explain how acute coronary events could be reduced by lipid lowering therapy without accompanying regression of coronary atherosclerosis seen on angiography.

Part of the motivation for producing the working paper, said Yl-Herttuala, was to provide general clinicians with greater guidance. "The whole field can be really confusing. After patients have been treated with statins for two or three years family doctors can be really concerned that they see no changes on angiograms. In such cases there's a danger that they may decide to stop life saving treatment."

The position paper reviewed the current state of knowledge around unstable plaques exploring the role of inflammation, chemokines, growth factors, platelets, angiogenesis and smoking. Evidence for therapies such as statins, antiplatelet therapies, and antihypertensive treatments were outlined, in addition to reviewing new approaches ,such as the development of drugs targeting the fibrous cap. Detection of unstable plaques through genetic testing, biomarkers and imaging was also explored.

"The single most important advance that would help us to tackle vulnerable plaques would be to have a non invasive imaging tool that would allow us to identify at risk patients before they suffer an event," said Yl-Herttuala.

The position paper is also calling for more translational research into imaging, biomarkers and the development of new treatments. "There is a real need to develop treatments specifically for the purpose of stabilising vulnerable plaques. At the moment we only have treatments that were discovered to have a beneficial effect through serendipity," said Weber.


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-492-947-756
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Forecast calls for nanoflowers to help return eyesight
2. CMAJ calls on federal government to protect Canadians from unsafe drugs
3. Report Blames Speedy FDA Clearance for Medical Device Recalls
4. Calls Go Out to Revive the Traditional Physical
5. Tufts University calls for moderate approach to teaching personalized genomic testing
6. FDA Panel Calls for Safety Review of Mercury in Dental Fillings
7. FDA Calls for New Warnings on Some Prostate Cancer Drugs
8. International Menopause Society calls upon medical community to improve the vaginal health of postmenopausal women
9. European Nurse Society calls to action on breakthrough cancer pain
10. Prostate cancer community calls for better early detection and treatment
11. IAS calls for an end to harassment, intimidation and imprisonment of HIV professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... ... In any business, follow up is critical to success. It is the ... treatment, there will always be some patients who can’t or won’t make a immediate ... when it comes to presenting treatment. After the patient leaves, most practices end ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, ... and 31st at The Four Seasons Hotel Boston. , The Boston CEO ... offering exclusive access to key decision makers who influence deal making and investment. ...
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head ... bold recipes for Memorial Day entertaining that are sure to satisfy your guests’ ... fresh sliced meats and cheeses featured in these refreshingly balanced recipes are packed ...
(Date:5/26/2017)... ... May 26, 2017 , ... Silver Birch of Hammond, a new assisted ... more than four acres of land at 5620 Sohl Avenue in Hammond, serves older ... building includes 125 studio and one-bedroom apartments. Each of the private apartments at Silver ...
(Date:5/26/2017)... Colorado (PRWEB) , ... May 26, 2017 , ... ... will be this year’s recipient of proceeds from its 14th Annual Clays for ... 46700 E. County Road 30, Bennett, Colorado. , As part of BluSky’s ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
Breaking Medicine Technology: